Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 701.3 INR 10.91% Market Closed
Market Cap: 231.8B INR

Eris Lifesciences Ltd
Total Other Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Eris Lifesciences Ltd
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Total Other Income
₹176.7m
CAGR 3-Years
-6%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Other Income
₹12.5B
CAGR 3-Years
6%
CAGR 5-Years
35%
CAGR 10-Years
24%
Cipla Ltd
NSE:CIPLA
Total Other Income
₹10.4B
CAGR 3-Years
40%
CAGR 5-Years
30%
CAGR 10-Years
19%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Other Income
₹20.1B
CAGR 3-Years
47%
CAGR 5-Years
26%
CAGR 10-Years
11%
Lupin Ltd
NSE:LUPIN
Total Other Income
₹2.8B
CAGR 3-Years
59%
CAGR 5-Years
-5%
CAGR 10-Years
2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Other Income
-₹487.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
231.7B INR
Industry
Pharmaceuticals

Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue. The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.

ERIS Intrinsic Value
1 350.7 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Total Other Income?
Total Other Income
176.7m INR

Based on the financial report for Sep 30, 2025, Eris Lifesciences Ltd's Total Other Income amounts to 176.7m INR.

What is Eris Lifesciences Ltd's Total Other Income growth rate?
Total Other Income CAGR 5Y
10%

Over the last year, the Total Other Income growth was -31%. The average annual Total Other Income growth rates for Eris Lifesciences Ltd have been -6% over the past three years , 10% over the past five years .

Back to Top